穿支动脉粥样硬化病患者静脉溶栓后不缓解超早期使用替罗非班的有效性和安全性研

李佳蓉,张莹,朱利利,宋良,禹萌,李浩然,付胜奇

神经损伤与功能重建 ›› 2026, Vol. 21 ›› Issue (10) : 565-569.

PDF(977 KB)
中国科技核心期刊
美国《化学文摘》CAS数据库收录
日本科学技术振兴机构数据库收录
湖北省优秀期刊
中国知网网络首发期刊
PDF(977 KB)
神经损伤与功能重建 ›› 2026, Vol. 21 ›› Issue (10) : 565-569. DOI: 10.16780/j.cnki.sjssgncj.20260366
论著

穿支动脉粥样硬化病患者静脉溶栓后不缓解超早期使用替罗非班的有效性和安全性研

  • 李佳蓉,张莹,朱利利,宋良,禹萌,李浩然,付胜奇
作者信息 +

Efficacy and Safety of Ultra-Early Use of Tirofiban in Branch Atheromatous Disease Patients Without Symptom Relief After Intravenous Thrombolysis

  • LI Jiarong, ZHANG Ying, ZHU Lili, SONG Liang, YU Meng, LI Haoran, FU Shengqi
Author information +
文章历史 +

摘要

目的:探讨静脉溶栓后神经功能缺损症状未见缓解的穿支动脉粥样硬化病(branch atheromatous disease,BAD)患者,超早期应用替罗非班的有效性及安全性。方法:回顾性分析2021年1月至2024年12月郑州人民医院卒中中心收治的符合BAD诊断标准且完成静脉溶栓治疗但症状未缓解的患者。根据是否在超早期接受替罗非班治疗,将患者分为替罗非班组和对照组。随访至90 d,采用改良Rankin量表(modified rankin scale,mRS)评估患者远期临床预后,记录症状性颅内出血、其他不良事件及死亡情况,比较2组患者的疗效与安全性。结果:共纳入130例患者,其中替罗非班组62例,对照组68例。替罗非班组在治疗后24~72 h及7 d时的美国国立卫生研究院卒中量表(national institute of health stroke scale,NIHSS)评分均低于对照组[3(2,5) vs 3(3,6),2(1,4) vs 3(2,4)],替罗非班组在90 d时mRS评分≤1分及mRS评分≤2分比例高于对照组(66.13% vs 42.65%,72.58% vs 54.41%),差异有统计学意义(均P<0.05)。替罗非班组1例患者发生症状性颅内出血,对照组未发生症状性颅内出血。死亡事件方面,替罗非班组2例患者死亡,死亡原因分别为肺炎、长期卧床后深静脉血栓脱落继发肺栓塞;对照组1例患者死于卒中后肺部感染。替罗非班组其他不良事件发生率为11.29%,对照组为7.35%,统计分析显示,差异均无统计学意义(均P>0.05)。 结论:对于BAD静脉溶栓后症状未缓解的患者,超早期应用替罗非班可显著改善预后,且安全性较高。

Abstract

Objective: To investigate the efficacy and safety of ultra-early tirofiban administration in patients with branch atheromatous disease (BAD) who show no relief of neurological deficit symptoms after intravenous thrombolysis. Methods: A retrospective analysis was conducted on patients admitted to the Stroke Center of Zhengzhou People’s Hospital from January 2021 to December 2024, who met the diagnostic criteria for BAD, completed intravenous thrombolysis but had no symptomatic relief. According to whether they received ultra-early tirofiban treatment, the patients were divided into a tirofiban group and a control group. Patients were followed up to 90 days, the modified Rankin Scale (mRS) was used to evaluate their long-term clinical prognosis, symptomatic intracranial hemorrhage, other adverse events and deaths were recorded, and the efficacy and safety of the two groups were compared. Results: A total of 130 patients were enrolled, including 62 in the tirofiban group and 68 in the control group. The National Institute of Health Stroke Scale (NIHSS) scores of the tirofiban group at 24~72 h and 7 days after treatment were lower than those of the Control group [3 (2,5) vs 3 (3,6), 2 (1,4) vs 3 (2,4)], and the proportions of patients with mRS score ≤1 and mRS score ≤2 at 90 days in the tirofiban group were higher than those in the control group (66.13% vs 42.65%, 72.58% vs 54.41%), with statistically significant differences (all P<0.05). One patient in the tirofiban group developed symptomatic intracranial hemorrhage, while no symptomatic intracranial hemorrhage occurred in the control group. In terms of death events, 2 patients in the tirofiban group died, with the causes being pneumonia and pulmonary embolism secondary to deep vein thrombosis detachment after long-term bed rest respectively; 1 patient in the Control group died of post-stroke pulmonary infection. The incidence of other adverse events was 11.29% in the tirofiban group and 7.35% in the Control group, and statistical analysis showed no significant differences (all P>0.05). Conclusion: For patients with BAD who have no symptomatic relief after intravenous thrombolysis, ultra-early application of tirofiban can significantly improve the prognosis with relatively high safety.

关键词

穿支动脉粥样硬化病;替罗非班;预后;静脉溶栓

Key words

branch atheromatous disease; tirofiban; prognosis; intravenous thrombolysis

引用本文

导出引用
李佳蓉,张莹,朱利利,宋良,禹萌,李浩然,付胜奇. 穿支动脉粥样硬化病患者静脉溶栓后不缓解超早期使用替罗非班的有效性和安全性研[J]. 神经损伤与功能重建. 2026, 21(10): 565-569 https://doi.org/10.16780/j.cnki.sjssgncj.20260366
LI Jiarong, ZHANG Ying, ZHU Lili, SONG Liang, YU Meng, LI Haoran, FU Shengqi. Efficacy and Safety of Ultra-Early Use of Tirofiban in Branch Atheromatous Disease Patients Without Symptom Relief After Intravenous Thrombolysis[J]. Neural Injury and Functional Reconstruction. 2026, 21(10): 565-569 https://doi.org/10.16780/j.cnki.sjssgncj.20260366

基金

河南省科技攻关计划项目(穿支动脉粥样硬化病患者TEG参数、CD62p和sCD36的表达及替罗非班治疗对其水平和临床结局的影响,No. 262102310007);河南省医学科技攻关计划联合共建项目(基于CT灌注成像联合hs-CRP/HDL-C比值、NAR、GDF15在穿支动脉粥样硬化病诊治中的应用价值,No. LHGJ20240880);河南省医学科技项目(基于外泌体 miRNA 联合高分辨 MRI 的穿支动脉粥样硬化病 END 风险预测模型构建及临床研究,No. SBGJ202602102)

PDF(977 KB)

Accesses

Citation

Detail

段落导航
相关文章

/

〈 〉